
TandemAI: An advanced AI company revolutionizing drug discovery.
TandemAI was founded with the mission to revolutionize the drug discovery process through advanced artificial intelligence and physics-based platforms. The company aims to integrate innovative technologies into traditional workflows, thereby accelerating the discovery and development of new drugs. Their flagship product, TandemViz, empowers research teams by providing a comprehensive, integrated platform for drug discovery. TandemAI focuses on leveraging AI to streamline and enhance the efficiency of pharmaceutical research and development.
Notable figures affiliated with TandemAI include leading experts in AI and drug discovery, though specific names are not publicly highlighted. The company has garnered attention through significant media coverage and industry events, such as webinars on AI and computational tools. TandemAI's key achievements include the successful integration of their AI platform into existing drug discovery processes, significantly reducing time and costs associated with bringing new drugs to market. Their impact is marked by a transformative approach that promises to redefine the future of pharmaceutical research.

Zephyr AI
zephyrai.bio

DeepCure
deepcure.ai

Phronesis Artificial Intelligence
phronesisai.com

Terray Therapeutics
terraytx.com

Cognaisent
cognaisent.com

Biosim

Numerion Labs
numerionlabs.ai

AMPLY Discovery
amplydiscovery.com

Iambic Therapeutics
iambic.ai
Atommap

Pathos AI
pathos.com

Turing Labs Inc.
turingsaas.com

Atomic AI
atomic.ai

Harmonic Discovery

Cedience
cedience.com
Companies similar to TandemAI include Zephyr AI, DeepCure, Phronesis Artificial Intelligence and Terray Therapeutics.
TandemAI was founded in 2021.
TandemAI's headquarters is located in New York City, NY, US.
TandemAI's most recent funding round was for $35M (USD) in March 2023.
As of Mar 1, 2023, TandemAI has raised a total of $60M (USD).
TandemAI has 46 employees as of Feb 4, 2024.